DERMATA THERAPEUTICS INC (DRMA) Stock Analyst Ratings
NASDAQ:DRMA - Nasdaq - US2498454055 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to DRMA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 477.36% above the current price.
DRMA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about DRMA.
In the previous month the buy percentage consensus was at a similar level.
DRMA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-08-21 | Maxim Group | Maintains | Buy -> Buy |
| 2023-03-23 | Maxim Group | Maintains | Buy |
| 2021-09-21 | Brookline Capital | Initiate | Buy |
| 2021-09-14 | Maxim Group | Initiate | Buy |